WO2011001936A1 - 血液成分の分離システム、分離材 - Google Patents
血液成分の分離システム、分離材 Download PDFInfo
- Publication number
- WO2011001936A1 WO2011001936A1 PCT/JP2010/060975 JP2010060975W WO2011001936A1 WO 2011001936 A1 WO2011001936 A1 WO 2011001936A1 JP 2010060975 W JP2010060975 W JP 2010060975W WO 2011001936 A1 WO2011001936 A1 WO 2011001936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- separation
- rich fraction
- blood cell
- blood
- leukocyte
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0218—Multiple bag systems for separating or storing blood components with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43838—Ultrafine fibres, e.g. microfibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/12—Special parameters characterising the filtering material
- B01D2239/1208—Porosity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/12—Special parameters characterising the filtering material
- B01D2239/1233—Fibre diameter
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
Definitions
- the present invention relates to a method for separating a red blood cell rich fraction, a white blood cell rich fraction, and / or a platelet rich fraction from a body fluid containing each blood cell component.
- the present invention also relates to a separation material and a separation method capable of selectively collecting a mononuclear cell-rich fraction including hematopoietic stem cells among leukocytes.
- An erythrocyte product is a blood product that is used when bleeding and erythrocytes are deficient, or when oxygen is deficient due to reduced function of erythrocytes. Therefore, leukocytes that induce side effects such as abnormal immune reaction and graft-versus-host disease (GVHD) are unnecessary, and it is necessary to remove leukocytes with a filter. In some cases, platelets may be removed in addition to leukocytes.
- GVHD graft-versus-host disease
- a platelet preparation is a blood preparation used for patients who are bleeding or tend to bleed due to a lack of blood coagulation factors. Centrifugation removes unnecessary cells and components other than platelets and collects only the necessary platelet components.
- hematopoietic stem cell transplantation for the treatment of leukemia and solid cancer has been actively performed, and cells (white blood cells, particularly mononuclear cells) necessary for treatment have been separated and administered.
- umbilical cord blood is attracting attention in addition to bone marrow and peripheral blood because of its advantages such as low burden on donors and excellent proliferation ability.
- menstrual blood it has been suggested that there are abundant stem cells in menstrual blood, and menstrual blood that has been discarded may be used as a valuable source of stem cells.
- leukocytes especially mononuclear cells
- banking for kin blood has become popular
- leukocytes are separated and purified for the purpose of preventing red blood cell hemolysis due to cryopreservation.
- red blood cells, platelets, and white blood cells can be obtained from the same source such as blood, bone marrow, and umbilical cord blood, so that necessary cells are wasted in the conventional separation method. Therefore, there is an urgent need for a separation technique that can be rapidly realized without requiring a complicated operation for separating red blood cells, white blood cells, and platelets from the same source.
- Non-Patent Document 1 discloses a method for reducing the contamination rate of granulocytes.
- the contamination rate of granulocytes is still high and the granulocyte contamination rate is higher than the present rate. Reduction is required (Non-Patent Document 1).
- An object of the present invention is to provide a method for quickly and easily separating a erythrocyte-rich fraction, a leukocyte-rich fraction, and a platelet-rich fraction from a body fluid containing each blood cell component without requiring centrifugation. Furthermore, a separation material and a separation method capable of obtaining a mononuclear cell-rich fraction having a particularly low granulocyte contamination rate among leukocytes are also provided.
- the present inventors have used a certain type of blood cell separator.
- leukocytes and platelets are captured by a separating material to obtain an erythrocyte-rich fraction, and then the leukocytes captured by the blood cell separating material are collected using a separating solution to obtain a leukocyte-rich fraction.
- the present inventors have found that it can be separated into an erythrocyte-rich fraction, a leukocyte-rich fraction, and a platelet-rich fraction, thereby completing the present invention.
- the present invention uses a blood cell separator that can capture leukocytes and platelets and that can separate and recover a leukocyte-rich fraction, and a body fluid containing each blood cell component is separated into an erythrocyte-rich fraction, a leukocyte-rich fraction, and a platelet-rich fraction.
- This method is completely different from conventional leukocyte removal filters and leukocyte capture and recovery methods using materials through which platelets substantially pass as described in Patent Documents 1 and 2.
- the present inventors can efficiently separate a mononuclear cell-rich fraction that contains a large amount of mononuclear cells among leukocytes by using a non-woven fabric having a specific honey and fiber diameter as a blood cell separator. I found it.
- the present invention is a method for separating a body fluid into blood cell components, (A) capturing the white blood cells and platelets in the blood cell separator by contacting the body fluid with the blood cell separator; Obtaining a red blood cell rich fraction; (B) a step of separating a leukocyte-rich fraction from a blood cell separation material using a separation solution.
- the blood cell separator is filled in a container provided with an inlet and an outlet for body fluid, and the body fluid is passed through the inlet to be brought into contact with the blood cell separator.
- step (a) it is preferable to wash the erythrocytes remaining on the blood cell separation material with a washing liquid after contacting the body fluid with the blood cell separation material.
- step (b) it is preferable to separate and collect leukocytes by injecting a separation solution from the body fluid outlet side.
- the separation solution comprises saline, buffer, dextran, medium, or infusion.
- the body fluid is blood, bone marrow, umbilical cord blood, menstrual blood, or tissue extract.
- the solution previously brought into contact with the blood cell separation material contains physiological saline or a buffer solution.
- the blood separating material is preferably made of a nonwoven fabric, and the nonwoven fabric is preferably made of split fibers.
- the nonwoven fabric is preferably composed of polyester fiber, polypropylene fiber, nylon fiber, or acrylic fiber.
- the polyester fiber is preferably polyethylene terephthalate fiber or polybutylene terephthalate fiber.
- the nonwoven fabric is preferably nylon fiber, polypropylene fiber or polybutylene terephthalate fiber.
- the density K of the nonwoven fabric is 2.0 ⁇ 10 4 or more and 1.9 ⁇ 10 5 or less
- the fiber diameter is 1 ⁇ m or more and 15 ⁇ m or less
- the leukocyte-rich fraction is a mononuclear cell-rich fraction.
- a solution having a viscosity of 1 mPa ⁇ s or more and less than 5 mPa ⁇ s is preferably used.
- the platelet recovery rate in the leukocyte-rich fraction or mononuclear cell-rich fraction is preferably less than or equal to the leukocyte recovery rate, and the platelet recovery rate in the leukocyte-rich fraction or mononuclear cell-rich fraction is mononuclear cell recovery It is preferable that it is below the rate.
- the ratio of the mononuclear cell recovery rate to the granulocyte recovery rate in the leukocyte-rich fraction or the mononuclear cell-rich fraction is greater than 1.0.
- the leukocyte-rich fraction or mononuclear cell-rich fraction comprises hematopoietic stem cells, mesenchymal stem cells, or CD34 positive cells.
- the present invention also relates to an erythrocyte-rich fraction, leukocyte-rich fraction, or platelet-rich fraction separated by the above method.
- the present invention also provides a blood cell comprising a nonwoven fabric having a density K of 2.0 ⁇ 10 4 to 1.9 ⁇ 10 5 and a fiber diameter of 1 ⁇ m to 15 ⁇ m and capable of separating a mononuclear cell-rich fraction from a body fluid. It relates to a separating material.
- the blood cell separator is preferably composed of nylon fiber, polypropylene fiber or polybutylene terephthalate fiber.
- the present invention also relates to a blood cell separation device, characterized in that the blood cell separation material is filled in a container provided with a body fluid inlet and outlet in a stacked state.
- the present invention provides a container filled with the above-described blood cell separation material in a laminated state, a channel opening / closing means installed upstream on the inlet side of the container, a leukocyte-rich fraction collection means connected to the channel opening / closing means, and
- the present invention relates to a blood cell separation device having a separation solution introduction means installed downstream of the outlet side of a container.
- the present invention also relates to a separation solution having a viscosity of 1 mPa ⁇ s or more and less than 5 mPa ⁇ s for collecting leukocytes captured by a blood cell separation material or a nonwoven fabric.
- the separation solution preferably does not contain dextran.
- a body fluid is easily and quickly separated from a body fluid such as whole blood, bone marrow, umbilical cord blood, menstrual blood, tissue extract into a red blood cell rich fraction, a white blood cell rich fraction, and a platelet rich fraction. It becomes possible to do.
- a body fluid such as whole blood, bone marrow, umbilical cord blood, menstrual blood, tissue extract into a red blood cell rich fraction, a white blood cell rich fraction, and a platelet rich fraction. It becomes possible to do.
- a mononuclear cell-rich fraction can be obtained by using the nonwoven fabric of the present invention as a blood cell separator.
- the erythrocyte-rich fraction collected by the method of the present invention has a very low contamination rate with other blood cells and can be used for transfusion as it is.
- the leukocyte-rich fraction and mononuclear cell-rich fraction obtained by the method of the present invention have a very low erythrocyte contamination rate, and therefore, even if cryopreserved until use, there is very little adverse effect due to erythrocyte hemolysis.
- the filter filled with the separation material of the present invention in a container can be used in an aseptic closed system, the fraction collected aseptically can be amplified as it is to prepare cells.
- the blood cell separation material of the present invention can be provided as a filter for preparing therapeutic cells for regenerative medicine such as leukemia treatment, myocardial regeneration and blood vessel regeneration. Furthermore, since the leukocyte-rich fraction and the mononuclear cell-rich fraction obtained using the blood cell separation material of the present invention are hematopoietic stem cell-rich fractions, a cell source for regenerative medicine is prepared along with the preparation of a transfusion preparation. Therefore, it is very useful as a filter for this purpose, and it is possible to prepare a highly safe therapeutic cell with few side effects.
- Method for separating body fluid into blood cell components comprises: (A) capturing the white blood cells and platelets in the blood cell separator by contacting the body fluid with the blood cell separator, and obtaining a red blood cell rich fraction; (B) separating the leukocyte-rich fraction from the blood cell separator using the separation solution.
- the blood cell separator may be used without being put in the container, or the blood cell separator may be put in a container having an inlet and an outlet for body fluid. However, in consideration of practicality, the latter used in a container is preferred. Further, the blood cell separator may be treated with a body fluid in the form of a flat plate cut to an appropriate size, or may be treated in the form of a roll. When the blood cell separator is filled in a container having an inlet and an outlet for body fluid, the body fluid is brought into contact with the blood cell separator by passing through the inlet.
- (A) Body fluid feeding step In this step, a body fluid is injected into a container filled with a blood cell separator from the inlet side to capture white blood cells and platelets to obtain a red blood cell rich fraction.
- the body fluid means whole blood, bone marrow, umbilical cord blood, menstrual blood, and tissue extract, and these may be roughly separated.
- animal species There are no restrictions on animal species, and any animal may be used as long as it is a mammal such as a human, cow, mouse, rat, pig, monkey, dog, or cat.
- umbilical cord blood, bone marrow, and tissue can also be collected.
- citrate anticoagulation such as ACD (acid-citrate-dextrose), CPD (citrate-phosphate-dextrose), and CPDA (citrate-phosphate-dextrose-adenine) It may be anticoagulated with heparin, low molecular weight heparin, fusan (nafamostat methyl acid) or EDTA. If there is no influence according to the purpose for which each fraction is used, the preservation conditions of the body fluid are not questioned at all.
- ACD acid-citrate-dextrose
- CPD citrate-phosphate-dextrose
- CPDA citrate-phosphate-dextrose-adenine
- the body fluid When the body fluid is passed through from the body fluid inlet side of the container filled with the blood cell separation material, the body fluid may be sent from the container in which the body fluid is placed by a natural drop through a liquid feeding circuit or by a pump. Alternatively, a syringe containing body fluid may be directly connected to the container and the syringe pushed by hand.
- the separation efficiency decreases if the liquid feeding speed is too fast, and the processing time is too long if the liquid feeding speed is too slow, and examples include 0.1 mL / min to 100 mL / min, but are not limited thereto. It is not something.
- the pretreatment solution does not have to be the same as the solution used in the following cleaning step, but if it is the same, the solution bag can be shared.
- the amount of the pretreatment liquid is practically and preferably about 1 to 100 times that of the container filled with the blood cell separator.
- the blood cell separator After trapping leukocytes and platelets in the blood cell separator, the blood cell separator is washed. At this time, the erythrocytes accumulated in the container are efficiently collected and separated by passing the washing solution from the same direction. Since the washing liquid can mainly collect only red blood cells, it may be mixed with the liquid that has passed when the body fluid is injected to form a red blood cell rich fraction.
- the cleaning liquid When passing the cleaning liquid from the inflow side of the cleaning liquid in the same direction as the body fluid supplying step, the cleaning liquid may be supplied by natural fall through the circuit or may be supplied by a pump.
- the flow rate in the case of feeding with a pump is about the same as that in the body fluid feeding process, and is from 0.1 mL / min to 100 mL / min, but is not limited thereto.
- the amount of washing differs depending on the volume of the container. However, if the amount of washing is too small, the amount of red blood cell components remaining in the container increases, and if the amount of washing is too large, the separation efficiency is reduced and a great deal of time is required. It is preferable to wash with a volume of about 100 to 100 times.
- any solution may be used as long as it is possible to wash out only red blood cells, suppress the mixing of other blood cells in the leukocyte-rich fraction, and maintain the trapped state of blood cells.
- general buffer solutions such as physiological saline, Ringer's solution, medium used for cell culture, and phosphate buffer are preferable.
- a separation solution is injected into a container filled with a blood cell separation material in the direction opposite to the direction in which the body fluid passes (from the body fluid outlet side) to obtain a leukocyte-rich fraction.
- the reason for injecting the separation solution in the direction opposite to the direction in which the body fluid is passed is that the leukocyte collection rate in the leukocyte-rich fraction is higher when the separation solution is introduced from the outlet side.
- the separation solution can be put in a syringe or the like in advance, and the plunger of the syringe can be pushed out vigorously using a hand or a device.
- the amount of recovered liquid and the flow rate vary depending on the capacity and processing amount of the container, but the capacity is about 1 to 100 times that of the container, and the flow rate is preferably 0.5 mL / sec to 20 mL / sec, but is not limited thereto. Absent.
- the separation solution is not particularly limited as long as it is a hypotonic solution, and examples thereof include those that have been used as injections such as physiological saline and Ringer's solution, buffer solutions, cell culture media, infusion solutions, and the like.
- the viscosity of the collected liquid may be increased in order to increase the collection rate of the captured cells.
- albumin, fibrinogen, globulin, dextran, hydroxyethyl starch, hydroxyethyl cellulose, collagen, hyaluronic acid, gelatin and the like can be added to the above-mentioned separation solution, but are not limited thereto.
- the viscosity of the recovered liquid containing dextran or the like at a high concentration is 5 mPa ⁇ s or more and is often difficult to recover manually by using a syringe
- a separation solution containing no dextran or It is preferable to use a separation solution in which the dextran concentration is adjusted so that the viscosity is 1 mPa ⁇ s or more and less than 5 mPa ⁇ s.
- the blood cell component red blood cell rich fraction means that the recovery rate of red blood cells in the passage fraction is higher than the recovery rate of other blood cells (white blood cells or platelets), and the red blood cell recovery rate of the red blood cell rich fraction is 80% or more, preferably 90%. % Or more, more preferably 95% or more.
- the red blood cell recovery rate referred to here is obtained from a ratio obtained by dividing the total number of red blood cells in the red blood cell rich fraction by the total number of red blood cells before processing.
- the recovery rate calculated from the ratio of the total leukocyte count in the erythrocyte fraction divided by the total leukocyte count before treatment is 10% or less, preferably 5% or less.
- the recovery rate calculated from the ratio of the total platelet count in the erythrocyte fraction divided by the total platelet count before treatment is less than 60%, preferably 40% or less, more preferably 20 % Or less.
- the leukocyte-rich fraction separated and recovered using the method and blood cell separation material in the present invention means that any of the leukocyte recovery rate, mononuclear cell recovery rate, and granulocyte recovery rate in the recovered separation solution is other blood cells (red blood cells or It means that it is at least 1/2 times the recovery rate of platelets. This applies even if the recovery rate of lymphocytes is 1 ⁇ 2 or more of the recovery rate of other blood cells (red blood cells or platelets).
- the leukocyte recovery rate is 45% or more, preferably 60% or more, more preferably 80% or more.
- the leukocyte collection rate referred to here is obtained from a ratio obtained by dividing the total leukocyte count in the leukocyte-rich fraction by the total leukocyte count before treatment.
- the mononuclear cell recovery rate and granulocyte recovery rate can also be calculated from the same total number, but the mononuclear cell count and granulocyte count are calculated by multiplying the positive rate obtained by a flow cytometer or the like and the white blood cell count.
- the platelet recovery rate in the leukocyte-rich fraction or mononuclear cell-rich fraction is preferably less than or equal to the leukocyte recovery rate. Further, the platelet recovery rate in the leukocyte-rich fraction or the mononuclear cell-rich fraction is preferably not more than the mononuclear cell recovery rate.
- the leukocyte-rich fraction or mononuclear cell-rich fraction preferably contains hematopoietic stem cells, mesenchymal stem cells, and CD34 positive cells.
- the red blood cell recovery rate calculated from the ratio of the total number of red blood cells in the white blood cell rich fraction divided by the total number of red blood cells before treatment is 10% or less, preferably 5% or less.
- the platelet recovery rate calculated from the ratio obtained by dividing the total platelet count in the leukocyte-rich fraction by the total platelet count before treatment is 50% or less, preferably 25% or less, more preferably It is 10% or less, more preferably 5% or less.
- the platelet-rich fraction is the fraction of cells captured by the separation material after obtaining the leukocyte-rich fraction from the separation solution, and the platelet recovery rate captured by the separation material is the recovery rate of other blood cells (red blood cells or white blood cells). Means higher.
- the non-woven fabric described in the present invention having a density K of 2.0 ⁇ 10 4 or more and 1.9 ⁇ 10 5 or less and a fiber diameter of 1 ⁇ m or more and 15 ⁇ m or less is used, leukocytes in the fraction separated and recovered by the separation solution It is also possible to control the composition. For example, it can be used for the separation of mononuclear cells (lymphocytes + monocytes) and granulocytes, and a mononuclear cell rich composition (mononuclear cell rich fraction) can be obtained.
- Mononuclear cell-rich fraction means that the recovery rate of mononuclear cells in the fraction separated and recovered by the separation solution is higher than the recovery rate of granulocytes and other blood cell components (red blood cells or platelets) in the fraction.
- the value of mononuclear cell recovery rate / granulocyte recovery rate is larger than 1.0, preferably 1.2 times or more, more preferably 1.5 times or more.
- the material used for the blood cell separation material is not particularly limited, but from the viewpoint of sterilization resistance and cell safety, polyethylene terephthalate, polybutylene terephthalate, polyethylene, high density polyethylene, low density polyethylene, polyvinyl alcohol, Vinylidene chloride, rayon, vinylon, polypropylene, acrylic (polymethyl methacrylate, polyhydroxyethyl methacrylate, polyacrylonitrile, polyacrylic acid, polyacrylate), nylon, polyimide, aramid (aromatic polyamide), polyamide, cupra, carbon, phenol Natural polymers such as polyester, pulp, hemp, polyurethane, polystyrene, polycarbonate, synthetic polymers, agarose, cellulose, cellulose acetate, chitosan, chitin Child, inorganic materials and metals, such as glass.
- polyethylene terephthalate, polybutylene terephthalate, polypropylene, acrylic, nylon, polyurethane, and glass are preferable. These materials are not limited to a single type, and may be combined, mixed, and fused as necessary. Furthermore, if necessary, molecules having affinity for specific cells such as proteins, peptides, amino acids and saccharides may be immobilized.
- a particulate form, a nonwoven fabric, a woven fabric, sponge form, a porous body, a mesh form etc. are mentioned.
- a nonwoven fabric is more preferable because it can be easily produced and obtained.
- the nonwoven fabric is preferably composed of at least one of polyester fiber, polypropylene fiber, nylon fiber, and acrylic fiber.
- Polyester is preferably polyethylene terephthalate or polybutylene terephthalate because the separation efficiency of red blood cells and white blood cells is increased.
- the nonwoven fabric is more preferably made of nylon, polypropylene and / or polybutylene terephthalate because the separation efficiency of red blood cells and white blood cells is increased.
- Nonwoven fabric production methods can be broadly classified into wet and dry methods, and resin bonds, thermal bonds, spunlaces, needle punches, stitch bonds, spunbonds, melt blows, etc., but are limited to these production methods. There is no. However, melt blow and spun lace are more preferable because the blood cell separation efficiency is good when the fiber diameter is small. A material that is calendered or plasma treated may be used.
- a so-called split fiber obtained by dividing a composite single yarn into a plurality of fibers is also suitable because the fibers are intertwined in a complex manner and blood cell separation efficiency is good.
- the density K of the separating material that is, the basis weight (g / m 2 ) / thickness (m) is 1.0 ⁇ 10 4 or more and 5.0 ⁇ based on the separation efficiency of the red blood cell rich fraction, the white blood cell rich fraction, and the platelet rich fraction. It is preferably 10 5 or less.
- leukocytes in particular, when a mononuclear cell-rich fraction containing a large amount of mononuclear cells is collected, it is necessary to be 2.0 ⁇ 10 4 or more and 1.9 ⁇ 10 5 or less.
- the density K indicates the basis weight (g / m 2 ) / thickness (m), which can also be expressed as weight (g) / unit volume (m 3 ). Therefore, the density K can also be obtained by measuring the weight (g) per unit volume (m 3 ) regardless of the form of the separating material. At the time of measurement, measurement is performed without deformation so as not to apply pressure. For example, the thickness in a non-contact state can be measured by using a CCD laser direction sensor (manufactured by Keyence Corporation, LK-035). Of course, when the basis weight or thickness is described in the catalog of the material to be used, the density K may be obtained from the basis weight (g / m 2 ) / thickness (m).
- the fiber diameter of the separating material needs to be 1 ⁇ m or more and 15 ⁇ m or less. If it is thinner than 1 ⁇ m, clogging is likely to occur. If it is thicker than 15 ⁇ m, leukocytes and / or platelets are not trapped in the separation material, and the contamination rate of leukocytes and / or platelets in the erythrocyte-rich fraction increases, and leukocyte-rich Separation efficiency of fractions and platelet-rich fractions is significantly reduced. From the viewpoint of improving the separation efficiency, it is preferably 1 ⁇ m to 10 ⁇ m, more preferably 1 ⁇ m to 7 ⁇ m, and particularly preferably 1 ⁇ m to 5 ⁇ m.
- the fiber diameter is the width of the fiber in the direction perpendicular to the fiber axis, and the fiber diameter is measured by taking a photograph of a separating material made of a nonwoven fabric with a scanning electron microscope and obtaining it from the scale described in the photograph. It can be obtained by averaging the calculated diameters. That is, the fiber diameter described in the present invention means an average value of the fiber diameters measured as described above, and is an average value of 50 or more, desirably 100 or more. However, when a large number of fibers are overlapped, when other fibers are obstructed and the width cannot be measured, or when fibers having remarkably different diameters are mixed, the fiber diameter is calculated excluding the data.
- the fiber diameter is calculated separately because the smaller the fiber diameter, the greater the influence on the separation efficiency.
- the thin fiber diameter is defined as the fiber diameter of the nonwoven fabric. Even if the two types of fiber diameters are different, for example, if the diameter is 7 ⁇ m or less, the fiber diameter is calculated as the same.
- two or more of the above-described separation materials of the present invention may be used in combination, or a separation material of the present invention and a separation material other than the present invention may be used in combination. That is, as long as at least one type of separation material having the above-described material, density K and fiber diameter is used, for example, even when a separation material having a fiber diameter of 15 to 30 ⁇ m is used at the same time, Included in the category.
- the blood cell separation device of the present invention is obtained by filling a blood cell separation material into a container provided with an inlet and an outlet for body fluid.
- the blood cell separation device is practically equipped with a cleaning solution and an inlet and an outlet for the separation solution, a red blood cell rich fraction collection means, a white blood cell rich fraction collection means (or a mononuclear cell rich fraction collection means), etc. at the same time. It is preferable.
- the collection means may be a bag.
- the blood cell separation device includes a container filled with a blood cell separation material in a stacked state, a channel opening / closing means installed upstream on the inlet side of the container, a leukocyte-rich fraction collection means connected to the channel opening / closing means, and a container It is preferable to have an introduction means for the separation solution installed downstream of the outlet side.
- the blood cell separation device has an inlet through which the body fluid flows in and an outlet through which the body fluid flows, and further, a cleaning solution for flowing the erythrocytes accumulated in the container independently of the body fluid inlet or the body fluid inlet.
- a cleaning solution for flowing the erythrocytes accumulated in the container independently of the body fluid inlet or the body fluid inlet.
- the inlet / outlet of the washing liquid attached to the container may share the inlet / outlet of the body fluid, and the circuit on the inlet side may be connected to the blood bag and the washing solution bag through a channel opening / closing means such as a three-way stopcock. .
- the separation solution inlet may be shared with the body fluid outlet, and the separation solution recovery port may be shared with the body fluid inlet.
- the circuit may be connected to each bag, syringe, or the like via a three-way cock.
- FIG. 3 shows an example of a blood cell component separation system using the blood cell separator of the present invention.
- the container is preferably provided with a body fluid storage bag, a separation solution collection bag for collecting a leukocyte-rich fraction, a red blood cell-rich fraction collection bag, and the like.
- a body fluid storage bag preferably provided with a separation solution collection bag for collecting a leukocyte-rich fraction, a red blood cell-rich fraction collection bag, and the like.
- Each bag is preferably used after use, and may be shaped like a commonly used blood bag, but may be a flat cartridge type.
- a collection bag for the leukocyte-rich fraction and the mononuclear cell-rich fraction a bag capable of cell culture, a bag having resistance to cryopreservation, and the like may be selected according to the purpose.
- the container When filling the blood cell separation material into the container, the container may be compressed and filled, or the container may be filled without being compressed. What is necessary is just to select suitably according to the material etc. of a blood cell separator.
- a blood cell separator it is preferable to cut a blood cell separator made of a nonwoven fabric into an appropriate size and use it in a single layer or a laminated state in a thickness of about 1 mm to 200 mm. From the standpoint of separation efficiency of each fraction, 1.5 mm to 150 mm is more preferable, and 2 mm to 100 mm is more preferable.
- the thickness is preferably about 1 mm to 50 mm and used in a single layer or a laminated state. From the standpoint of separation efficiency of each fraction, 1.5 mm to 40 mm is more preferable, and further preferably 2 mm to 35 mm.
- the blood cell separator may be wound into a roll and filled into a container.
- blood cells When used in the form of a roll, blood cells may be separated by treating the body fluid from the inside to the outside of the roll, or conversely, the body fluid may be treated from the outside to the inside of the roll. good.
- the form, size, and material of the container filled with the blood cell separation material are not particularly limited.
- the form of the container may be any form such as a sphere, a container, a cassette, a bag, a tube, or a column.
- Preferable specific examples include, for example, a translucent cylindrical container having a container of about 0.1 to 400 mL and a diameter of about 0.1 to 15 cm; a rectangular or square piece having a length of about 0.1 to 20 cm, and a thickness.
- the present invention is not limited to these examples.
- the container can be made using any structural material.
- the structural material include non-reactive polymers, biocompatible metals, alloys, and glass.
- Non-reactive polymers include acrylonitrile polymers such as acrylonitrile butadiene styrene terpolymers; polytetrafluoroethylene, polychlorotrifluoroethylene, copolymers of tetrafluoroethylene and hexafluoropropylene, halogenated polymers such as polyvinyl chloride; polyamides and polyimides , Polysulfone, polycarbonate, polyethylene, polypropylene, polyvinyl chloride acrylic copolymer, polycarbonate acrylonitrile butadiene styrene, polystyrene, polymethylpentene and the like.
- materials having sterilization resistance include polypropylene, polyvinyl chloride, polyethylene, polyimide, polycarbonate, polysulfone, and polymethylpentene.
- Example 1 A container having a thickness of 6 mm and a diameter of 18 mm is filled with 28 polypropylene non-woven fabrics (fiber diameter 3.5 ⁇ m, density K 8.3 ⁇ 10 4 g / m 3 ) in a laminated state, and 45 mL of physiological saline is first syringed from the inlet side. The solution was passed by hand using Next, 10 mL of fresh citrate anticoagulated blood was passed at 2.5 mL / min, and then 10 mL of physiological saline was passed from the same direction. Thereafter, 30 mL of 10% FBS-added MEM medium was collected manually by a syringe from the direction opposite to the flow direction.
- Blood count of pre-treated blood, red blood cell rich fraction, and white blood cell rich blood count were measured with a blood cell counter (Sysmex Corp., K-4500), and each blood cell recovery rate in each fraction Was calculated. Furthermore, the blood before treatment and the collected separated solution were hemolyzed with FACS Lysing Solution, and then the mononuclear cell positive rate and granulocyte positive rate were determined with a flow cytometer (manufactured by Nippon Becton Dickinson Co., Ltd., FACSCanto). And the respective positive rates were multiplied to calculate the total number of mononuclear cells and the total number of granulocytes.
- the ratio obtained by dividing the total number of mononuclear cells and the total number of granulocytes in the collected separated solution by the total number of mononuclear cells and the total number of granulocytes before treatment was defined as the mononuclear cell recovery rate and the granulocyte recovery rate, respectively.
- the results are shown in Table 1.
- Example 2 The same operation as in Example 1 was carried out except that 28 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter 2.5 ⁇ m, density K1.0 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 3 The same operation as in Example 1 was carried out except that 28 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter 3.8 ⁇ m, density K1.2 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 4 The same operation as in Example 1 was carried out except that 44 sheets of polyethylene terephthalate nonwoven fabric (fiber diameter 4.1 ⁇ m, density K1.9 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 5 The same operation as in Example 1 was carried out except that 44 sheets of acrylic nonwoven fabric (fiber diameter 4.7 ⁇ m, density K1.4 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 6 The same operation as in Example 1 was performed except that 22 nonwoven fabrics (fiber diameter 10 ⁇ m, density K1.6 ⁇ 10 5 g / m 3 ) composed of polyethylene terephthalate and polypropylene split fibers were filled in a laminated state. The results are shown in Table 1.
- Example 7 Filled with 22 non-woven fabrics (fiber diameter 10 ⁇ m, density K1.4 ⁇ 10 5 g / m 3 ) composed of polyethylene terephthalate and nylon split fibers, and ACD anticoagulated fresh cow instead of citric acid anticoagulated The same operation as in Example 1 was performed except that 10 mL of blood was used. The results are shown in Table 1.
- Example 8 Nylon nonwoven fabric (fiber diameter 5.0 ⁇ m, density K1.3 ⁇ 10 5 g / m 3 ) was packed in 33 layers, CPD anticoagulated fresh human blood instead of 10 mL of citrate anticoagulated fresh bovine blood The same operation as in Example 1 was performed except that 10 mL was used. The results are shown in Table 1.
- Example 9 The same operation as in Example 8 was performed except that 30 sheets of polypropylene nonwoven fabric (fiber diameter 2.4 ⁇ m, density K5.6 ⁇ 10 4 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 10 The same operation as in Example 8 was carried out except that 28 sheets of polypropylene nonwoven fabric (fiber diameter 3.5 ⁇ m, density K8.3 ⁇ 10 4 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 11 The same operation as in Example 8 was carried out except that 28 sheets of polypropylene nonwoven fabric (fiber diameter 5.7 ⁇ m, density K1.2 ⁇ 10 5 g / m 3 ) were filled. The results are shown in Table 1.
- Example 12 The same operation as in Example 8 was carried out except that 84 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter 1.8 ⁇ m, density K9.1 ⁇ 10 4 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 13 The same operation as in Example 8 was performed except that 28 sheets of a polybutylene terephthalate nonwoven fabric (fiber diameter 2.5 ⁇ m, density K1.0 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 14 The same operation as in Example 8 was carried out except that 28 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter 3.8 ⁇ m, density K1.2 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 15 The same operation as in Example 8 was carried out except that 28 sheets of a polybutylene terephthalate nonwoven fabric (fiber diameter 5.3 ⁇ m, density K1.1 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 16 The same operation as in Example 13 was performed except that CPD anticoagulated porcine umbilical cord blood was used instead of 10 mL of CPD anticoagulated fresh human blood. The results are shown in Table 1.
- Example 17 The same operation as in Example 13 was performed except that 10% dextran sugar injection was used in place of the 10% FBS-added MEM medium. The results are shown in Table 1.
- Example 18 The same operation as in Example 7 was performed except that citrate anticoagulated bovine blood was used instead of ACD anticoagulated human blood, and physiological saline was used instead of MEM medium supplemented with 10% FBS. The results are shown in Table 1.
- Example 19 The same procedure as in Example 3 was performed except that 10 mL of CPD anticoagulated porcine bone marrow was used instead of 10 mL of fresh citrate anticoagulated blood. The results are shown in Table 1.
- Example 1 The same operation as in Example 8 was carried out except that 40 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter 16 ⁇ m, density K5.1 ⁇ 10 4 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 2 The same operation as in Example 1 was conducted except that 36 sheets of non-woven fabric made of glass and polyethylene terephthalate (fiber diameter less than 0.59 ⁇ m / 9.3 ⁇ m, density K2.0 ⁇ 10 5 g / m 3 ) were filled. Carried out. The results are shown in Table 1.
- Example 3 The same operation as in Example 1 was carried out except that 24 sheets of non-woven fabric made of glass and polyethylene terephthalate (fiber diameter less than 0.84 ⁇ m / 8.4 ⁇ m, density K2.2 ⁇ 10 5 g / m 3 ) were filled. Carried out. The results are shown in Table 1.
- Example 4 The same operation as in Example 1 was carried out except that 56 nonwoven fabrics (fiber diameter 30 ⁇ m, density K3.2 ⁇ 10 5 g / m 3 ) were filled in a laminated state. The results are shown in Table 1.
- Example 5 The same operation as in Example 1 was carried out except that 6 sheets of non-woven fabric (fiber diameter 22 ⁇ m, density K2.1 ⁇ 10 5 g / m 3 ) made of acrylic and polyethylene terephthalate were filled in a laminated state. The results are shown in Table 1.
- Example 20 The viscosity at 25 ° C. of MEM medium supplemented with 10% FBS, 10% dextran sugar injection, and physiological saline was measured. The viscosities were 2.9 mPa ⁇ s, 5.3 mPa ⁇ s, and 1.1 mPa ⁇ s, respectively.
- the relationship between the density K of the nonwoven fabric and the mononuclear cell recovery rate is shown in FIG.
- the density K was calculated by dividing the basis weight by the thickness.
- the thickness was measured using a dial thickness gauge with a gauge diameter of 25 mm and a pressure of 0.7 kPa.
- the basis weight was calculated by measuring the weight of a nonwoven fabric cut into 10 cm square.
- the relationship between the fiber diameter of the nonwoven fabric and the mononuclear cell recovery rate is shown in FIG.
- the fiber diameter was calculated from an average value obtained by taking a photograph of the nonwoven fabric with a scanning electron microscope, measuring 100 fiber diameters from the scale described in the photograph, and measuring the fiber diameter.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
(a)体液を血球分離材と接触させることにより白血球と血小板を血球分離材に捕捉し、
赤血球豊富分画を得る工程と、
(b)分離溶液を用いて血球分離材から白血球豊富分画を分離する工程
とを含むことを特徴とする分離方法に関する。
本発明の、体液を各血球成分に分離する方法は、
(a)体液を血球分離材と接触させることにより白血球と血小板を血球分離材に捕捉し、赤血球豊富分画を得る工程と、
(b)分離溶液を用いて血球分離材から白血球豊富分画を分離する工程
とを含む。
この工程では、血球分離材が充填された容器に体液を入口側より注入し、白血球と血小板を捕捉させ赤血球豊富分画を得る。
血球分離材を充填した容器に体液の通液とは逆方向(体液出口側)より分離溶液を注入し、白血球豊富分画を得る。体液の通液とは逆方向より分離溶液を注入する理由は、出口側から導入する方が、白血球豊富分画中の白血球回収率が高くなるためである。分離溶液を注入する際には、分離溶液を予めシリンジ等に入れておき、シリンジのプランジャーを手や機器を用いて勢い良く押し出すことにより実行できる。回収液量や流速は、容器の容量や処理量により異なるが、容器の1倍から100倍程度の容量で、流速0.5mL/secから20mL/secが好ましいが、これらに限定されるものではない。
赤血球豊富分画とは通過分画中の赤血球回収率が他血球(白血球または血小板)の回収率よりも高いことであり、赤血球豊富分画の赤血球回収率は80%以上、好ましくは90%以上、より好ましくは95%以上である。ここで言う赤血球回収率とは、赤血球豊富分画中の総赤血球数を処理前の総赤血球数で割った割合から求められる。
血球分離材に用いられる材料は特に限定されないが、滅菌耐性や細胞への安全性の観点からは、ポリエチレンテレフタート、ポリブチレンテレフタレート、ポリエチレン、高密度ポリエチレン、低密度ポリエチレン、ポリビニルアルコール、塩化ビニリデン、レーヨン、ビニロン、ポリプロピレン、アクリル(ポリメチルメタクリレート、ポリヒドロキシエチルメタクリレート、ポリアクリルニトリル、ポリアクリル酸、ポリアクリレート)、ナイロン、ポリイミド、アラミド(芳香族ポリアミド)、ポリアミド、キュプラ、カーボン、フェノール、ポリエステル、パルプ、麻、ポリウレタン、ポリスチレン、ポリカーボネートなどの合成高分子、アガロース、セルロース、セルロースアセテート、キトサン、キチンなどの天然高分子、ガラスなどの無機材料や金属等が挙げられる。このうち、ポリエチレンテレフタレート、ポリブチレンテレフタレート、ポリプロピレン、アクリル、ナイロン、ポリウレタン、ガラスであることが好ましい。これらの材料は一種類の単独とは限らず、必要に応じて材料を複合・混合・融合して用いても良い。さらには必要ならば、蛋白質、ペプチド、アミノ酸、糖類など特定の細胞に親和性のある分子を固定しても構わない。
本発明の血球分離デバイスは、血球分離材を、体液の入口と出口を供えた容器に充填して得られる。
厚さ6mm直径18mmの容器に、ポリプロピレン製不織布(繊維径3.5μm、密度K8.3×104g/m3)28枚を積層状態で充填し、まず生理食塩水45mLを入口側よりシリンジを用いて手押しで通液した。次にクエン酸抗凝固の新鮮ウシ血液10mLを2.5mL/minで通液し、次に同方向より生理食塩水10mLを通液した。その後、通液とは逆方向より10%FBS添加MEM培地30mLをシリンジを用いて手押しで回収した。処理前血液の血算、赤血球豊富分画の血算、白血球豊富分画中の血算を血球カウンター(シスメックス(株)製、K-4500)により測定し、各分画中の各血球回収率を算出した。さらに、処理前の血液、回収した分離溶液をFACS Lysing Solutionで溶血後、フローサイトメーター(日本ベクトン・ディッキンソン(株)製、FACSCanto)により単核球陽性率、顆粒球陽性率を求め、白血球数と各陽性率を掛けあわせて総単核球数及び総顆粒球数を算出した。回収した分離溶液中の総単核球数・総顆粒球数を処理前の総単核球数・総顆粒球数で割った割合を各々単核球回収率・顆粒球回収率とした。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径2.5μm、密度K1.0×105g/m3)を28枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径3.8μm、密度K1.2×105g/m3)を28枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ポリエチレンテレフタレート製不織布(繊維径4.1μm、密度K1.9×105g/m3)を44枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
アクリル製不織布(繊維径4.7μm、密度K1.4×105g/m3)を44枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ポリエチレンテレフタレートとポリプロピレンの分割繊維から成る不織布(繊維径10μm、密度K1.6×105g/m3)を22枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ポリエチレンテレフタレートとナイロンの分割繊維から成る不織布(繊維径10μm、密度K1.4×105g/m3)を22枚積層状態で充填したこと、クエン酸抗凝固の代わりにACD抗凝固の新鮮ウシ血液10mLを用いること以外は実施例1と同様の操作を実施した。結果は表1に示した。
ナイロン製不織布(繊維径5.0μm、密度K1.3×105g/m3)を33枚積層状態で充填したこと、クエン酸抗凝固の新鮮ウシ血液10mLの代わりにCPD抗凝固新鮮ヒト血液10mLを用いること以外は実施例1と同様の操作を実施した。結果は表1に示した。
ポリプロピレン製不織布(繊維径2.4μm、密度K5.6×104g/m3)を30枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリプロピレン製不織布(繊維径3.5μm、密度K8.3×104g/m3)を28枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリプロピレン製不織布(繊維径5.7μm、密度K1.2×105g/m3)を28枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径1.8μm、密度K9.1×104g/m3)を84枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径2.5μm、密度K1.0×105g/m3)を28枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径3.8μm、密度K1.2×105g/m3)を28枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート製不織布(繊維径5.3μm、密度K1.1×105g/m3)を28枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
CPD抗凝固新鮮ヒト血液10mLの代わりにCPD抗凝固ブタ臍帯血を用いたこと以外は実施例13と同様の操作を実施した。結果は表1に示した。
10%FBS添加MEM培地の代わりに10%デキストラン糖注を用いること以外は実施例13と同様の操作を実施した。結果は表1に示した。
ACD抗凝固ヒト血液の代わりにクエン酸抗凝固ウシ血液を用い、10%FBS添加MEM培地の代わりに生理食塩水を用いること以外は実施例7と同様の操作を実施した。結果は表1に示した。
クエン酸抗凝固の新鮮ウシ血液10mLの代わりにCPD抗凝固ブタ骨髄10mLを用いる以外は実施例3と同様の操作を実施した。結果は表1に示した。
ポリブチレンテレフタレート不織布(繊維径16μm、密度K5.1×104g/m3)を40枚積層状態で充填したこと以外は実施例8と同様の操作を実施した。結果は表1に示した。
ガラスとポリエチレンテレフタレートから成る不織布(繊維径0.59μm未満/9.3μm、密度K2.0×105g/m3)を36枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ガラスとポリエチレンテレフタレートから成る不織布(繊維径0.84μm未満/8.4μm、密度K2.2×105g/m3)を24枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
ビニロンから成る不織布(繊維径30μm、密度K3.2×105g/m3)を56枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
アクリルとポリエチレンテレフタレートから成る不織布(繊維径22μm、密度K2.1×105g/m3)を6枚積層状態で充填したこと以外は実施例1と同様の操作を実施した。結果は表1に示した。
10%FBS添加MEM培地、10%デキストラン糖注、および生理食塩水の、25℃における粘度を測定した。粘度はそれぞれ2.9mPa・s、5.3mPa・s、1.1mPa・sであった。
2 血球分離材の充填された容器
3 体液バッグ
4 洗浄液バッグ
(兼プライミング液バッグ)
5 赤血球豊富分画回収バッグ
6 白血球豊富分画回収バッグ
(単核球豊富分画回収バッグ)
7 回収ポート
8、9、10 三方活栓
11~17 回路
Claims (26)
- 体液を各血球成分に分離する方法であって、
(a)体液を血球分離材と接触させることにより白血球と血小板を血球分離材に捕捉し、
赤血球豊富分画を得る工程と、
(b)分離溶液を用いて血球分離材から白血球豊富分画を分離する工程
とを含むことを特徴とする分離方法。 - 血球分離材が体液の入口と出口を供えた容器に充填され、体液を該入口から通液することにより血球分離材と接触させることを特徴とする請求項1記載の分離方法。
- (a)工程において、体液を血球分離材と接触させた後に、血球分離材に残存する赤血球を洗浄液で洗浄する請求項1または2記載の分離方法。
- (b)工程において、体液の出口側から分離溶液を注入し白血球を分離回収することを特徴とする請求項2または3記載の分離方法。
- 分離溶液が生理食塩水、緩衝液、デキストラン、培地、または輸液を含むことを特徴とする請求項1~4のいずれかに記載の分離方法。
- 体液が血液、骨髄、臍帯血、月経血、または組織抽出物である請求項1~5のいずれかに記載の分離方法。
- (a)工程の体液を血球分離材と接触させる前に、予め溶液を血球分離材と接触させることを特徴とする請求項1~6のいずれかに記載の分離方法。
- 予め血球分離材と接触させる溶液が生理食塩水、または緩衝液を含むことを特徴とする請求項7記載の分離方法。
- 血液分離材が不織布から成る請求項1~8のいずれかに記載の分離方法。
- 不織布がポリエステル繊維、ポリプロピレン繊維、ナイロン繊維、またはアクリル繊維で構成される請求項9記載の分離方法。
- ポリエステル繊維がポリエチレンテレフタレート繊維、またはポリブチレンテレフタレート繊維である請求項10記載の分離方法。
- 不織布がナイロン繊維、ポリプロピレン繊維、またはポリブチレンテレフタレート繊維で構成される請求項10記載の分離方法。
- 不織布が分割繊維から構成される請求項9記載の分離方法。
- 不織布の密度Kが2.0×104以上1.9×105以下、繊維径が1μm以上15μm以下であり、白血球豊富分画が単核球豊富分画である請求項9~13のいずれかに記載の分離方法。
- 分離溶液として、粘度が1mPa・s以上5mPa・s未満の溶液を用いる請求項1~14のいずれかに記載の分離方法。
- 白血球豊富分画中または単核球豊富分画中の血小板回収率が白血球回収率以下であることを特徴とする請求項1~15のいずれかに記載の分離方法。
- 白血球豊富分画中または単核球豊富分画中の血小板回収率が単核球回収率以下であることを特徴とする請求項1~15のいずれかに記載の分離方法。
- 白血球豊富分画中または単核球豊富分画中の、単核球回収率の顆粒球回収率に対する比が1.0より大きいことを特徴とする請求項1~15のいずれかに記載の分離方法。
- 白血球豊富分画または単核球豊富分画が、造血幹細胞、間葉系幹細胞、またはCD34陽性細胞を含むことを特徴とする請求項1~15記載のいずれかに記載の分離方法。
- 請求項1から請求項13に記載された方法により分離された赤血球豊富分画、白血球豊富分画、または血小板豊富分画。
- 密度Kが2.0×104以上1.9×105以下、繊維径が1μm以上15μm以下である、体液から単核球豊富分画を分離可能な不織布からなる血球分離材。
- 不織布がナイロン繊維、ポリプロピレン繊維、またはポリブチレンテレフタレート繊維で構成される請求項21記載の血球分離材。
- 請求項21または22記載の血球分離材が体液の入口と出口を供えた容器に積層状態で充填されていることを特徴とする血球分離デバイス。
- さらに、前記容器の入口側の上流に設置された流路開閉手段、
流路開閉手段につながれた白血球豊富分画回収手段、および
前記容器の出口側の下流に設置された分離溶液の導入手段
を有する請求項23記載の血球分離デバイス。 - 血球分離材または不織布に捕捉された白血球を回収するための溶液の粘度が1mPa・s以上5mPa・s未満である分離溶液。
- デキストランを含まないことを特徴とする請求項25記載の分離溶液。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800295258A CN102471762A (zh) | 2009-06-30 | 2010-06-28 | 血液成分的分离***、分离材料 |
CA2766250A CA2766250C (en) | 2009-06-30 | 2010-06-28 | Blood component separation system and separation material |
SG2011097011A SG177407A1 (en) | 2009-06-30 | 2010-06-28 | Blood component separation system and separation material |
US13/381,433 US9649424B2 (en) | 2009-06-30 | 2010-06-28 | Blood component separation system and separation material |
JP2011520911A JP6162359B2 (ja) | 2009-06-30 | 2010-06-28 | 血液成分の分離システム、分離材 |
EP10794105.6A EP2450431B1 (en) | 2009-06-30 | 2010-06-28 | Blood component separation system and separation material |
KR1020117030454A KR101674517B1 (ko) | 2009-06-30 | 2010-06-28 | 혈액 성분의 분리 시스템, 분리재 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-156383 | 2009-06-30 | ||
JP2009156383 | 2009-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011001936A1 true WO2011001936A1 (ja) | 2011-01-06 |
Family
ID=43411012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/060975 WO2011001936A1 (ja) | 2009-06-30 | 2010-06-28 | 血液成分の分離システム、分離材 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9649424B2 (ja) |
EP (1) | EP2450431B1 (ja) |
JP (2) | JP6162359B2 (ja) |
KR (1) | KR101674517B1 (ja) |
CN (2) | CN107362397A (ja) |
CA (1) | CA2766250C (ja) |
SG (1) | SG177407A1 (ja) |
WO (1) | WO2011001936A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016505014A (ja) * | 2013-01-12 | 2016-02-18 | セスカ セラピューティクス, インコーポレイテッド | 自己骨髄由来の幹細胞の迅速な注入 |
JP5900491B2 (ja) * | 2011-04-21 | 2016-04-06 | ニプロ株式会社 | 細胞培養方法及び細胞培養キット |
WO2016121766A1 (ja) * | 2015-01-26 | 2016-08-04 | 宇部興産株式会社 | 細胞を分離、除去、及び解析する方法 |
WO2018139583A1 (ja) | 2017-01-27 | 2018-08-02 | 公益財団法人神戸医療産業都市推進機構 | 単核球分離装置及び単核球分離方法 |
JP2019024426A (ja) * | 2017-07-31 | 2019-02-21 | 株式会社カネカ | 細胞分離装置、及び単核球を含む細胞含有液を取得する方法 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2450431B1 (en) | 2009-06-30 | 2020-01-01 | Kaneka Corporation | Blood component separation system and separation material |
DE102009029194A1 (de) | 2009-09-04 | 2011-04-07 | Kimberly-Clark Worldwide, Inc., Neenah | Abtrennung gefärbter Stoffe aus wasserhaltigen Flüssigkeiten |
JP5975985B2 (ja) * | 2011-04-11 | 2016-08-23 | 株式会社カネカ | 単核球調製材、及び前記調製材を利用した単核球調製方法 |
US9220646B2 (en) | 2012-03-30 | 2015-12-29 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with improved stain decolorization |
WO2013161679A1 (ja) | 2012-04-27 | 2013-10-31 | 株式会社カネカ | 有核細胞捕捉フィルターまたはこれを利用した有核細胞調製法 |
US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
TWI719468B (zh) * | 2012-07-24 | 2021-02-21 | 日商日產化學股份有限公司 | 培養基組成物、其用途、細胞或組織之培養方法及細胞或組織培養物 |
US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
US20150320918A1 (en) * | 2012-12-14 | 2015-11-12 | Bhc Technology Holdings Llc | Point of care isolation and concentration of blood cells |
CN103361311B (zh) * | 2013-08-07 | 2014-12-10 | 济南赛尔生物科技有限公司 | 利用清洗一次性使用去白细胞塑料血袋获取白细胞的方法 |
US9237975B2 (en) | 2013-09-27 | 2016-01-19 | Kimberly-Clark Worldwide, Inc. | Absorbent article with side barriers and decolorizing agents |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
EP3140417B1 (en) * | 2014-05-09 | 2021-04-21 | Reelabs Private Limited | Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders |
TWI571276B (zh) * | 2014-12-26 | 2017-02-21 | 國立高雄大學 | 血液分離萃取方法及其裝置 |
EP3070164A1 (en) | 2015-03-20 | 2016-09-21 | Medical Biobank Swiss Institute SA/AG (MBSI) | System and method for providing isolated concentrated multipotent stromal cells for administration |
EP3311857B1 (en) * | 2015-06-17 | 2024-04-10 | Asahi Kasei Medical Co., Ltd. | Blood-processing filter |
US20180185562A1 (en) * | 2015-06-17 | 2018-07-05 | Asahi Kasei Medical Co., Ltd. | Filter element for blood processing filter, blood processing filter, and blood processing method |
CN108700565B (zh) * | 2015-10-07 | 2021-10-29 | 善威生物私人有限公司 | 血液制备和图谱分析 |
CN113980894B (zh) * | 2021-12-27 | 2022-03-15 | 深圳博雅感知医疗科技有限公司 | 制备骨髓浓缩细胞的方法及其用于治疗卵巢早衰的用途 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01224325A (ja) * | 1988-03-03 | 1989-09-07 | Terumo Corp | 白血球分離材の製法 |
JPH0277263A (ja) * | 1988-09-14 | 1990-03-16 | Asahi Medical Co Ltd | 血球分離材および血球分離フィルター |
JPH08104643A (ja) * | 1994-10-05 | 1996-04-23 | Asahi Medical Co Ltd | 赤血球除去方法 |
WO1998032840A1 (fr) | 1997-01-24 | 1998-07-30 | Asahi Medical Co., Ltd. | Procede de separation des cellules |
JP2001078757A (ja) * | 1999-09-16 | 2001-03-27 | Asahi Medical Co Ltd | 細胞分離方法及び細胞分離用流体 |
JP2001518792A (ja) | 1997-04-08 | 2001-10-16 | ポール・コーポレーション | 血液製剤から希少細胞を採集する方法 |
JP2004121144A (ja) * | 2002-10-04 | 2004-04-22 | Asahi Medical Co Ltd | 単核球の採取方法 |
WO2006025371A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | 顆粒球吸着材 |
WO2007046501A1 (ja) * | 2005-10-21 | 2007-04-26 | Kaneka Corporation | 幹細胞の分離材および分離方法 |
JP2007289076A (ja) * | 2006-04-25 | 2007-11-08 | Kaneka Corp | 脂肪組織から幹細胞を採取するのに適した細胞分離装置、およびその方法 |
JP2008022822A (ja) * | 2006-07-25 | 2008-02-07 | Kaneka Corp | 成体幹細胞分離・培養システム |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL88081A0 (en) * | 1987-10-20 | 1989-06-30 | Pall Corp | Device and method for depletion of the leucocyte content of blood and blood components |
CA1329559C (en) | 1988-03-03 | 1994-05-17 | Keiji Naoi | Leukocyte separator and method of making the same |
AU617265B2 (en) * | 1988-06-23 | 1991-11-21 | Asahi Medical Co. Ltd. | Method for separating blood into blood components, and blood components separator unit |
JP3157519B2 (ja) * | 1990-11-30 | 2001-04-16 | テルモ株式会社 | 血液成分分離システム |
JP3088764B2 (ja) * | 1991-01-21 | 2000-09-18 | テルモ株式会社 | 血液成分分離方法 |
EP0591980B1 (en) * | 1992-10-07 | 1999-05-06 | Asahi Medical Co., Ltd. | Leukocyte-removing filter device and system |
JPH06246156A (ja) | 1993-02-24 | 1994-09-06 | Kanegafuchi Chem Ind Co Ltd | 細胞吸着体およびそれを用いる細胞の分離法 |
JP3938973B2 (ja) * | 1997-05-19 | 2007-06-27 | 旭化成メディカル株式会社 | 細胞分離方法 |
JP4412621B2 (ja) * | 1997-01-24 | 2010-02-10 | 旭化成クラレメディカル株式会社 | 細胞分離方法 |
JP3517359B2 (ja) * | 1998-09-14 | 2004-04-12 | テルモ株式会社 | 細胞分離・回収装置および細胞の分離・回収方法 |
US6926915B1 (en) | 1999-03-30 | 2005-08-09 | Netech, Inc. | Method for selectively separating blood cells by using lectin |
US7150834B2 (en) | 2003-07-31 | 2006-12-19 | Arryx, Inc. | Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components |
ITTO20020736A1 (it) * | 2002-08-21 | 2004-02-22 | Fresenius Hemocare Italia Srl | Filtro per leucociti e suo impiego per l'impoverimento di prodotti del sangue da leucociti. |
JP4245324B2 (ja) | 2002-10-09 | 2009-03-25 | 旭化成クラレメディカル株式会社 | 単球の分離回収方法 |
CN101072572B (zh) * | 2003-07-09 | 2013-12-11 | 华沙整形外科股份有限公司 | 富含***生长成分的骨髓组分的分离及其促进***形成的用途 |
JP2005224787A (ja) | 2004-02-15 | 2005-08-25 | Eiichi Tamiya | 不溶性物質の分離方法及び不溶性物質分離デバイス |
EP1709983B1 (en) * | 2004-12-28 | 2009-12-23 | CaridianBCT, Inc. | Apparatus and method for separating a volume of whole blood into four components |
EP2450431B1 (en) | 2009-06-30 | 2020-01-01 | Kaneka Corporation | Blood component separation system and separation material |
-
2010
- 2010-06-28 EP EP10794105.6A patent/EP2450431B1/en active Active
- 2010-06-28 JP JP2011520911A patent/JP6162359B2/ja active Active
- 2010-06-28 CN CN201710217805.5A patent/CN107362397A/zh active Pending
- 2010-06-28 SG SG2011097011A patent/SG177407A1/en unknown
- 2010-06-28 CN CN2010800295258A patent/CN102471762A/zh active Pending
- 2010-06-28 CA CA2766250A patent/CA2766250C/en not_active Expired - Fee Related
- 2010-06-28 KR KR1020117030454A patent/KR101674517B1/ko active IP Right Grant
- 2010-06-28 WO PCT/JP2010/060975 patent/WO2011001936A1/ja active Application Filing
- 2010-06-28 US US13/381,433 patent/US9649424B2/en active Active
-
2015
- 2015-08-27 JP JP2015167819A patent/JP6208186B2/ja active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01224325A (ja) * | 1988-03-03 | 1989-09-07 | Terumo Corp | 白血球分離材の製法 |
JPH0277263A (ja) * | 1988-09-14 | 1990-03-16 | Asahi Medical Co Ltd | 血球分離材および血球分離フィルター |
JPH08104643A (ja) * | 1994-10-05 | 1996-04-23 | Asahi Medical Co Ltd | 赤血球除去方法 |
WO1998032840A1 (fr) | 1997-01-24 | 1998-07-30 | Asahi Medical Co., Ltd. | Procede de separation des cellules |
JP2001518792A (ja) | 1997-04-08 | 2001-10-16 | ポール・コーポレーション | 血液製剤から希少細胞を採集する方法 |
JP2001078757A (ja) * | 1999-09-16 | 2001-03-27 | Asahi Medical Co Ltd | 細胞分離方法及び細胞分離用流体 |
JP2004121144A (ja) * | 2002-10-04 | 2004-04-22 | Asahi Medical Co Ltd | 単核球の採取方法 |
WO2006025371A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | 顆粒球吸着材 |
WO2007046501A1 (ja) * | 2005-10-21 | 2007-04-26 | Kaneka Corporation | 幹細胞の分離材および分離方法 |
JP2007289076A (ja) * | 2006-04-25 | 2007-11-08 | Kaneka Corp | 脂肪組織から幹細胞を採取するのに適した細胞分離装置、およびその方法 |
JP2008022822A (ja) * | 2006-07-25 | 2008-02-07 | Kaneka Corp | 成体幹細胞分離・培養システム |
Non-Patent Citations (1)
Title |
---|
TRANSFUSION, vol. 45, 2005, pages 1899 - 1908 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5900491B2 (ja) * | 2011-04-21 | 2016-04-06 | ニプロ株式会社 | 細胞培養方法及び細胞培養キット |
JP2016505014A (ja) * | 2013-01-12 | 2016-02-18 | セスカ セラピューティクス, インコーポレイテッド | 自己骨髄由来の幹細胞の迅速な注入 |
WO2016121766A1 (ja) * | 2015-01-26 | 2016-08-04 | 宇部興産株式会社 | 細胞を分離、除去、及び解析する方法 |
JPWO2016121766A1 (ja) * | 2015-01-26 | 2017-10-26 | 宇部興産株式会社 | 細胞を分離、除去、及び解析する方法 |
WO2018139583A1 (ja) | 2017-01-27 | 2018-08-02 | 公益財団法人神戸医療産業都市推進機構 | 単核球分離装置及び単核球分離方法 |
JP2019024426A (ja) * | 2017-07-31 | 2019-02-21 | 株式会社カネカ | 細胞分離装置、及び単核球を含む細胞含有液を取得する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6208186B2 (ja) | 2017-10-04 |
US20120141975A1 (en) | 2012-06-07 |
SG177407A1 (en) | 2012-02-28 |
CN107362397A (zh) | 2017-11-21 |
JP2016013130A (ja) | 2016-01-28 |
JPWO2011001936A1 (ja) | 2012-12-13 |
CA2766250C (en) | 2018-08-14 |
JP6162359B2 (ja) | 2017-07-12 |
US9649424B2 (en) | 2017-05-16 |
KR101674517B1 (ko) | 2016-11-09 |
EP2450431B1 (en) | 2020-01-01 |
CA2766250A1 (en) | 2011-01-06 |
EP2450431A4 (en) | 2017-12-20 |
CN102471762A (zh) | 2012-05-23 |
KR20120098403A (ko) | 2012-09-05 |
EP2450431A1 (en) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6208186B2 (ja) | 血液成分の分離システム、分離材 | |
JP5944832B2 (ja) | 白血球または単核球の分離方法、分離材 | |
JP5975985B2 (ja) | 単核球調製材、及び前記調製材を利用した単核球調製方法 | |
JP6707031B2 (ja) | 細胞分離材および細胞分離方法 | |
JP6143746B2 (ja) | 有核細胞捕捉フィルターまたはこれを利用した有核細胞調製法 | |
JP6409371B2 (ja) | フィルター内の***部の比率を最適化したフィルター | |
JP2013036818A (ja) | 腫瘍細胞の濃縮方法及び分離材 | |
WO2016002505A1 (ja) | フィルター内の***部の外形を最適化したフィルター | |
JP2012139142A (ja) | 造血幹細胞分離材または分離方法 | |
JP6379042B2 (ja) | 赤血球の除去方法 | |
JP3938973B2 (ja) | 細胞分離方法 | |
JP4043094B2 (ja) | 細胞分離器 | |
JP4135894B2 (ja) | 白血球除去フィルターに残留する白血球が除去された血液を回収する方法、回収装置および回収システム | |
JP4640991B2 (ja) | 単球選択捕捉材料 | |
JP2012120458A (ja) | 細胞の分離器具。 | |
JPH10201470A (ja) | 細胞分離方法及び細胞浮遊液 | |
JP2000325071A (ja) | 細胞分離回収方法 | |
JP2020195330A (ja) | 細胞分離フィルター装置、及び細胞濃縮液の製造方法 | |
JP2012120457A (ja) | プライミング装置機能付き細胞分離装置およびそれを用いたプライミング法。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080029525.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10794105 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011520911 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20117030454 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2766250 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5148/KOLNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010794105 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13381433 Country of ref document: US |